

---

**Statistical Analysis Plan Addendum**

Drug Substance K-877

Protocol Number K-877-301

Edition Number 1.0

Date 21 October 2019

---

---

**A Phase 3, Multi-Center, Placebo-Controlled, Randomized, Double-Blind, 12-Week Study With a 40-Week, Active-Controlled, Double-Blind Extension to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting Triglyceride Levels  $\geq 500$  mg/dL and  $< 2000$  mg/dL and Normal Renal Function**

---

**Investigational Product:** K-877

**Protocol Number:** K-877-301

**Original Protocol Version 1.0:** 13 September 2016

**Protocol Version 2.0:** 18 August 2017

**SAP Version:** 1.0

**SAP Date:** 19 October 2016

**SAP Version:** 2.0

**SAP Date:** 21 June 2019

**SAP Addendum Version:** 1.0

**SAP Addendum Date:** 21 October 2019








SAP ADDENDUM SIGNATURE PAGE

---

**A Phase 3, Multi-Center, Placebo-Controlled, Randomized, Double-Blind,  
12-Week Study With a 40-Week, Active-Controlled, Double-Blind  
Extension to Evaluate the Efficacy and Safety of K-877 in Adult Patients  
With Fasting Triglyceride Levels  $\geq 500$  mg/dL and  $< 2000$  mg/dL and  
Normal Renal Function**

---

We, the undersigned, have read and approved the SAP Addendum



# TABLE OF CONTENTS

|   |   |
|---|---|
| TITLE PAGE .....  | 1 |
| SIGNATURE PAGE .....  | 2 |
| 1. INTRODUCTION .....   | 4 |
| 2. DATA ANALYSIS CHANGES .....  | 4 |
| 2.1 Imputation error due to lab parameters with value of 0.....                     | 4 |
| 2.2 Secondary efficacy endpoints for lab parameters with a baseline value of 0..... | 5 |
| 3. DATA ANALYSIS CLARIFICATION.....   | 6 |
| 4. PRIMARY IMPUTATION METHOD .....  | 6 |
| 5. REFERENCES .....   | 7 |

## 1. INTRODUCTION

The statistical analysis plan, version 2.0, for study with protocol number K-877-301 was finalized on June 21, 2019. The study was finished with the database locked on August 23, 2019. The treatment code was unblinded on August 26, 2019. Due to issue in coding process for prior and concomitant medications coding and medical history coding in electronic data capture system, the database was corrected and locked again on September 11, 2019.

The study results were reviewed. After the systemic review, the decision was made to perform the post-lock data analysis change or clarification as described in this document.

Summary of changes:

- The primary imputation method in the SAP did not take into account the scenario of imputing missing data when observed data had a value of 0. We have specified all scenarios for the primary imputation method.
- The secondary efficacy endpoint, where data value of 0 is observed at baseline, will additionally include analysis for 'change from baseline to week 12' given percent change not being calculable for such lab parameters. However, for these lab parameters, analysis of percent change from baseline to week 12 will be performed using data where percent change from baseline is available.

■ [REDACTED]  
[REDACTED]  
[REDACTED]  
[REDACTED]

## 2. DATA ANALYSIS CHANGES

### 2.1 Imputation error due to lab parameters with value of 0

After database lock and unblinding, it was observed that some lab parameters had a value of 0 at baseline or at week 12 or both. With such values, the primary imputation, which includes log-transformation of lab values at baseline and week 12, returned an error. The following parameters from the K-877-301 study had a data value of 0 for lab parameters that resulted in an error for log transformation:

| Lab Category         | Parameter (Unit)              | Number of subjects with value 0 |         |
|----------------------|-------------------------------|---------------------------------|---------|
|                      |                               | Baseline                        | Week 12 |
| Lipoprotein Fraction | HDL Particles-Large (umol/L)  | 43                              | 23      |
| Lipoprotein Fraction | HDL Particles-Medium (umol/L) | 42                              | 54      |

|                      |  |     |     |
|----------------------|--|-----|-----|
| Lipoprotein Fraction | HDL Particles-Small (umol/L)                 | 0   | 1   |
| Lipoprotein Fraction | IDL Particles (nmol/L)                       | 18  | 18  |
| Lipoprotein Fraction | LDL Particles (total) (nmol/L)               | 1   | 1   |
| Lipoprotein Fraction | LDL Particles-Large (nmol/L)                 | 339 | 202 |
| Lipoprotein Fraction | LDL Particles-Small (nmol/L)                 | 3   | 3   |
| Lipoprotein Fraction | VLDL & Chylomicron Particles-Medium (nmol/L) | 20  | 13  |
| Lipoprotein Fraction | VLDL & Chylomicron Particles-Small (nmol/L)  | 86  | 65  |

It was decided post database lock that an extension to the existing pattern mixture model multiple imputation method with fully conditional specification methods will be applied to the above parameters to account for the observed data values of 0. This method is called the predictive mean matching method which uses a simulated regression model to impute values randomly from a set of observed values whose predicted values are close to the predicted value of the missing value.

## 2.2 Secondary efficacy endpoints for lab parameters with a baseline value of 0

The protocol defined one of the secondary endpoints as percent change from baseline to week 12 in lipoprotein fraction (nuclear magnetic resonance). Since a few lipoprotein parameters have one or multiple records with a baseline value of 0, the percent change cannot be determined for such records. In such cases, the secondary endpoints for the lipoprotein parameters will be evaluated additionally for change from baseline to week 12. Analysis for percent change from baseline will be performed for patients who do not have a value of 0 at baseline.

[REDACTED]

[REDACTED]  
[REDACTED]  
[REDACTED]  
[REDACTED]  
[REDACTED]

### **3. DATA ANALYSIS CLARIFICATION**

The changes in analysis described in sections 2.1 and 2.2 of this document were applied only to the lab parameters where lab value of 0 was observed at baseline or post-baseline. This change as well as the change in section 2.3 of this document will not impact the results for the primary endpoint as well as secondary endpoints that were tested in a hierarchical step-down manner.

### **4. PRIMARY IMPUTATION METHOD**

For the main analysis of the primary efficacy variable, missing Week 12 endpoint will be imputed using the pattern mixture model using the fully conditional specification method. This imputation method will include factors such as patient demographics, disease status, and baseline values. The imputation method was specified in the SAP Appendix 1, pages 25, 26 and 27.

It was found after database lock that there was an error imputing data with a value of 0 as the pattern mixture model using the fully conditional specification method utilized log transformation of the observed values. The parameters mentioned in section 2.1 of this document resulted in imputation error because of log transformation of 0 values. After reviewing the methodology in SAP, it was decided that this scenario would be handled using the predictive mean matching method as an extension to the pattern mixture model of imputation.

Below is a summary of description of the imputation using the predictive mean matching method:

In addition to following the same description of steps in Appendix 1 (in Pages 25-27) of the SAP version 2.0, any lab parameter with a 0 value at baseline or week 12 will utilize the following SAS code to include the predictive mean matching method to impute missing data.

#### **Step II a.**

```
PROC MI DATA= DATA21a OUT=IMOUT1a  
    MINIMUM=0 SEED=68756 NIMPUTE=100 ROUND=1E-10;  
VAR AGE SEX ETHNICITY COUNTRY BMI SBP DBP EGFR STATIN WEEK12; CLASS  
SEX ETHNICITY COUNTRY STATIN;  
FCS REGPMM; /* fully conditional specification method with predictive mean matching  
method.*/  
RUN;
```

#### **Step II b.**

```
PROC MI DATA=DATA22 OUT=IMOUT22  
    MINIMUM=0 SEED=63546 NIMPUTE=100 ROUND=1E-10;  
VAR AGE SEX ETHNICITY COUNTRY BMI SBP DBP EGFR STATIN BASE WEEK 4  
    WEEK8 WEEK12;  
CLASS SEX ETHNICITY COUNTRY STATIN;  
FCS REGPMM; /*fully conditional specification method with predictive mean matching  
method/*  
RUN;
```

### **Step III.**

```
PROC MI DATA= DATA21c OUT=IMOUT1c  
      MINIMUM=0 SEED=745369 NIMPUTE=100 ROUND=1E-10;  
BY TRT;  
VAR AGE SEX ETHNICITY COUNTRY BMI SBP DBP EGFR STATIN BASE WEEK4  
      WEEK8 WEEK12;  
CLASS SEX ETHNICITY COUNTRY STATIN;  
FCS REGPMM; /*fully conditional specification method with predictive mean matching  
method*/  
RUN;
```

## **5. REFERENCES**

- O'Kelly M, and Ratitch B (2014), *Clinical Trials with Missing Data: A Guide for Practitioners*, Willey, U.K.
- Dmitrienko A, and Koch G.G. (2017), *Analysis of Clinical Trials Using SAS: A Practical Guide, Second Edition*, SAS Institute